What makes this radiotherapeutic candidate and company unique is that it is the first to deploy the selective targeting of urokinase plasminogen activator receptor [uPAR]. It does so with the ...

received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical trials of investigational 18 F-CTT1057 ...

SEATTLE--(BUSINESS WIRE)--Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company ... cancer by CTT’s licensing partner AAA/Novartis. CTT1057 and CTT1403 serve ...

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients ... The Munich-based company has confirmed ...

Furthermore, the Company may pay up to $136.5 million in development and sales milestone payments and a tiered single-digit royalty on U.S. and European sales. The licensed radiotherapeutic ...

The Company plans to report these results after the close of market today. About NanoTx Therapeutics, Inc.NanoTx Therapeutics is radiotherapeutic company developing nanoliposomal-encapsulated ...

The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials next year.

AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central ...

Radiotherapeutic companies have been ideal, but what exactly makes this company ideal, especially with its Nano-monoclonal antibodies platform? That's because it has been able to incorporate a ...

Further company coverage: Sign up here. Future of Healthcategory US FDA approves Adaptimmune's therapy for rare type of cancer August 2, 2024 Boards, Policy & Regulationcategory US FDA says all ...